Functional imaging of HER2-positive metastatic breast cancer using 64Cu DOTA-trastuzumab positron emission tomography (PET)

被引：0
|
作者：
Mortimer, Joanne E.
Conti, Peter
Tong, Shan
Reyes, Jose
Carroll, Mary I.
Poku, Kofi
Colcher, David
Raubitschek, Andrew Antony
Bading, James R.
Miles, Joshua
机构：
[1] City Hope Canc Ctr, Beckman Res Inst, Duarte, CA USA
[2] USC, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
639
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [32] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [33] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [34] A Novel Method to Label Preformed Liposomes with 64CU for Positron Emission Tomography (PET) Imaging
    Seo, Jai Woong
    Zhang, Hua
    Kukis, David L.
    Meares, Claude F.
    Ferrara, Katherine W.
    BIOCONJUGATE CHEMISTRY, 2008, 19 (12) : 2577 - 2584
  • [35] Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET
    Shinsuke Sasada
    Hiroaki Kurihara
    Takayuki Kinoshita
    Masayuki Yoshida
    Natsuki Honda
    Tatsunori Shimoi
    Akihiko Shimomura
    Kan Yonemori
    Chikako Shimizu
    Akinobu Hamada
    Yousuke Kanayama
    Yasuyoshi Watanabe
    Yasuhiro Fujiwara
    Kenji Tamura
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 2146 - 2147
  • [36] Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET
    Sasada, Shinsuke
    Kurihara, Hiroaki
    Kinoshita, Takayuki
    Yoshida, Masayuki
    Honda, Natsuki
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Yonemori, Kan
    Shimizu, Chikako
    Hamada, Akinobu
    Kanayama, Yousuke
    Watanabe, Yasuyoshi
    Fujiwara, Yasuhiro
    Tamura, Kenji
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (12) : 2146 - 2147
  • [37] Synthesis and biological evaluation of new bifunctional chelators for targeted positron emission tomography (PET) imaging using 64Cu
    Sun, Xiang
    Sin, Inseok
    Kang, Chi Soo
    Chen, Yunwei
    Chong, Hyun-Soon
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [38] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [39] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [40] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
12345